Skip to main content

Affinity Asset Advisors, LLC

Position in CRNX — Crinetics Pharmaceuticals, Inc.

CIK 1773195 NEW YORK, NY

Position in CRNX

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$2,806,500
+$82,500 QoQ
Shares Held
75,000
0.0% QoQ
Ownership
0.071%
of shares outstanding
% of Portfolio
0.14%
of 13F equity value
Holder Rank
#88
of 266 holders
Holding Since
Sep 2023
12 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in CRNX Over Time

Shares Held

Position Value (USD)

Derivatives in CRNX

reported options exposure · as of Dec 31, 2023
CallValue
$0
CallShares
0
PutValue
$3,355,194
PutShares
94,300

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Affinity Asset Advisors, LLC holds $1,842,784,374 across 87 Biotechnology names. CRNX ranks #73 (0.2% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in CRNX

Export CSV
13 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $2,806,500 75,000
2026-03-31 $2,724,000 75,000
2025-12-31 $3,491,250 75,000
2025-09-30 $3,123,750 75,000
2025-06-30 $4,378,767 152,252
2025-03-31 $5,106,532 152,252
2024-12-31 $23,519,800 460,000
2024-09-30 $20,440,000 400,000
2024-06-30 $23,066,850 515,000
2024-03-31 $22,000,700 470,000
2023-12-31 $15,907,640 447,095
2023-12-31 $3,355,194 94,300
2023-09-30 $13,383,000 450,000